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Aims Non-invasive assessment of stable chest pain patients is a critical determinant of resource utilization and clinical out-
comes. Increasingly coronary computed tomography angiography (CCTA) with selective CCTA-derived fractional flow
reserve (FFRCT) is being used. The ADVANCE Registry, is a large prospective examination of using a CCTA and FFRCT
diagnostic pathway in real-world settings, with the aim of determining the impact of this pathway on decision-making,
downstream invasive coronary angiography (ICA), revascularization, and major adverse cardiovascular events (MACE).
...................................................................................................................................................................................................
Methods
and results
A total of 5083 patients with symptoms concerning for coronary artery disease (CAD) and atherosclerosis on CCTA
were enrolled at 38 international sites from 15 July 2015 to 20 October 2017. Demographics, symptom status, CCTA
and FFRCT findings, treatment plans, and 90 days outcomes were recorded. The primary endpoint of reclassification be-
tween core lab CCTA alone and CCTA plus FFRCT-based management plans occurred in 66.9% [confidence interval
(CI): 64.8–67.6] of patients. Non-obstructive coronary disease was significantly lower in ICA patients with FFRCT <_0.80
(14.4%) compared to patients with FFRCT >0.80 (43.8%, odds ratio 0.19, CI: 0.15–0.25, P< 0.001). In total, 72.3% of
subjects undergoing ICA with FFRCT <_0.80 were revascularized. No death/myocardial infarction (MI) occurred within
90 days in patients with FFRCT >0.80 (n= 1529), whereas 19 (0.6%) MACE [hazard ratio (HR) 19.75, CI: 1.19–326,
P = 0.0008] and 14 (0.3%) death/MI (HR 14.68, CI 0.88–246, P= 0.039) occurred in subjects with an FFRCT <_0.80.
...................................................................................................................................................................................................
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Conclusions In a large international multicentre population, FFRCT modified treatment recommendation in two-thirds of sub-
jects as compared to CCTA alone, was associated with less negative ICA, predicted revascularization, and identified
subjects at low risk of adverse events through 90 days.
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Introduction
Coronary computed tomography angiography (CCTA) has been
shown to be an effective non-invasive test in the diagnosis and treat-
ment planning for patients with stable chest pain and suspected cor-
onary artery disease (CAD).1–4 Coronary computed tomography
angiography is excellent at ruling out CAD, but its utility is diminished
by the limited ability to predict physiologically significant CAD as
defined by an abnormal invasive fractional flow reserve (FFR).5,6
Coronary computed tomography angiography-derived fractional
flow reserve (FFRCT) is a non-invasive physiological test that can as-
sess flow limitation across coronary stenoses with high diagnostic ac-
curacy and good correlation to invasive FFR.7 In addition, FFRCT has
been shown to reduce the incidence of negative referrals to invasive
coronary angiography (ICA) post-CCTA, thus increasing the eventual
revascularization rate.8–10 However, to date most of the data have
been limited to single centre populations and trial settings and
there remains concerns regarding the clinical application of FFRCT,
especially in areas of ‘greyzone’ uncertainty, where diagnostic
accuracy may be lower.
The Assessing Diagnostic Value of Non-invasive FFRCT in
Coronary Care (ADVANCE) registry was designed to observe the
‘real-world’ utility and impact of using FFRCT in a broad variety of
healthcare settings, geographical regions, and patient populations.
The study aimed to determine how the incremental information of
an anatomical combined with functional FFRCT would change clinical
decision-making, patient management, clinical outcomes, and re-
source utilization.
Methods
Patients being investigated for clinically suspected CAD with documented
atherosclerosis >30% degree stenosis (DS) on CCTA were prospectively
enrolled at 38 sites in Europe, North American, and Japan from 15 July
2015 to 20 October 2017. All subjects were clinically stable symptomatic
patients diagnosed with CAD by CCTA who met the following eligibility
criteria: age >18 years, ability to provide informed consent, and CAD
diagnosed on a diagnostic standard CCTA. Exclusion Criteria included:
poor quality CCTA, life expectancy <1 year, and an inability to comply
with follow-up requirements. All patients provided written informed con-
sent following Institutional Review Board review and approval.
Demographics, symptom status, CCTA and FFRCT findings, treatment
plans, and clinical outcomes through 90 days were recorded.
Management strategies
The site investigators were asked to report an initial management plan
and treatment strategy based on CCTA alone for each subject in accord-
ance with local guidelines for the practice and interpretation of CCTA.
The decision to further investigate CCTA results with FFRCT was
directed by the physician interpreting the scan with a recommendation to
consider FFRCT for stenoses in the 30–90% range. All FFRCT analyses
were performed in a single centre (HeartFlow, Redwood City, CA, USA).
Once the FFRCT result was made available, the site investigators were
asked to re-determine the treatment strategy based on the new informa-
tion of the CCTA combined with the locally interpreted FFRCT result.
A positive FFRCT was deemed to be a value <_0.80 in accordance with the
previous published invasive and non-invasive literature.11 Subsequent
clinical management decisions such as revascularization or medical ther-
apy rested at the discretion of the referring physician. The registry did not
dictate interpretation or management decisions.
A core laboratory [Duke Clinical Research Institute (DCRI), Durham,
NC, USA] blinded to clinical information, symptom status, and outcomes,
reviewed all CCTA and declared an independent management plan based
on CCTA alone. Coronary computed tomography angiography-derived
fractional flow reserve analyses were then made available to the core lab,
who then re-determined the subject specific treatment strategy for each
patient based on the CCTA and FFRCT results. This involved adjudication
of vessel- and lesion-specific ischaemia, measuring the FFRCT 2 cm distal
to focal lesions.
Management plan treatment strategies for both site and core labora-
tory consisted of the following options: (i) optimal medical therapy, (ii)
percutaneous coronary intervention (PCI), (iii) coronary artery bypass
grafting (CABG) surgery, or (iv) additional diagnostic testing required. If
revascularization was selected, vessel segments to be revascularized
were specified and the interpreter was asked to recommend either PCI
or CABG. In instances of high-risk anatomy such as; three-vessel disease,
or two vessel involving the left anterior descending (LAD) artery or left
main stem disease, a consensus reading of two reviewers determined the
appropriate revascularization strategy.
Study endpoints
The primary endpoint was the reclassification rate between CCTA alone
vs. CCTA and FFRCT-based management plans as determined by the
core laboratory. Secondary endpoints included: reclassification rate be-
tween CCTA-based and FFRCT-based management plans as determined
by the site; incidence of ICA demonstrating absence of obstructive CAD
(no coronary stenosis >50%); percutaneous and surgical revasculariza-
tion rates; and 90 days survival free from all cause or major adverse
cardiovascular events (MACE) inclusive of myocardial infarction (MI), all-
cause mortality or unplanned hospitalization for Acute Coronary
Syndrome (ACS) leading to revascularization. Event adjudication was per-
formed by an independent Clinical Events Committee using standard defi-
nitions, blinded to clinical, and computed tomographic data.
Statistical analysis
Continuous data are presented as mean (± standard deviation) or median
(interquartile range, IQR), categorical data as frequency and percentage.
Comparative statistics for net reclassification used the Mann–Whitney
and Kruskal–Wallis tests as appropriate. Unpaired t-test was used to
determine differences between anatomic severity and rates of positive
FFRCT. Univariable and multivariable logistic regression models using step-
3702 T.A. Fairbairn et al.
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..wise selection were used to estimate the odds of revascularization where
a P-value <0.1 was used for entry into the multivariable model. The fit of
the final model was assessed using the Log Likelihood and Akaike
Information Criterion. The v2 test of independence was used to assess if
negative catheterization and MI/death were independent of or associated
with minimum FFRCT strata (>0.8/<_0.8); in cases of low (expected cell
count <5) or zero cell counts, the Fisher’s exact test was used. Odds ratios
(ORs) and associated 95% confidence intervals (CIs) were calculated; in
cases of zero cell counts, relative risk and associated 95% CIs were calcu-
lated. A two-sided level of P< 0.05 was considered significant.
Study funding, design, data gathering, and
analysis
The ADVANCE Registry was funded by HeartFlow Inc., via individual
Clinical Study Agreements with each enrolling institution and with the
DCRI for Core Laboratory activities and Clinical Event Committee adjudi-
cation of adverse events. The trial database was housed in iMedNet.
HeartFlow and the independent Clinical Research Organization (CRO)
had access to iMedNet on the sponsor side. Principal Investigators, sub-
investigators, and study co-ordinators at each site had access to iMedNet
and were responsible for data entry. The Clinical Event Adjudication and
core lab databases were housed in iMedNet. Duke Clinical Research
Institute had access to this data for entry, resolving queries, and locking
data. The CRO was able to query this data. HeartFlow did not have access
to adjudication forms. The primary analysis was performed by the Principal
Investigators including Drs Patel, Leipsic, Nieman, and Akasaka, as well as
by Dr Fairbairn, with statistical and analytical support from Dr Rogers and
Ms Mullen. The manuscript was drafted by the Principal Investigators and
Dr Fairbairn. All authors reviewed the manuscript and approved of the
submitted manuscript.
Results
Demographic, risk, and coronary artery
disease risk factor distribution
Patient demographics and distribution of CAD computed tomog-
raphy angiography (CTA) findings are provided in Table 1. A total of
5083 patients were enrolled, of whom 4893 had CCTA submitted
for FFRCT (96.2%). A total of 190 subjects did not have their CCTA
examinations submitted for FFRCT analysis at the site discretion: 111
because the invasive treatment decision was made due to the severity
of the stenosis; 61 owing to minimal CAD; 9 because of multiple cor-
onary stents; 2 because of CCTA exams not acquired in a fashion ac-
ceptable for FFRCT analysis. Of the submitted CCTAs 4737 (96.8%)
were of adequate quality for analysis. 3.2% were rejected from FFRCT
analysis because of image quality. Angina (typical or atypical) was the
predominant symptom in 58%, with an average Diamond–Forrester
pre-test probability for obstructive coronary disease of 51.6%. There
....................................................................................................................................................................................................................
Table 1 Demographics, coronary artery disease risk factors, and symptom status
CTA only (n5346) FFRCT (n5 4737) Total (n5 5083)
Age (years) 64.3 (11.1) 66.1 (10.3) 66.0 (10.3)
Male gender 215 (62.1%) 3134 (66.2%) 3349 (65.9%)
Hypertension 210 (60.7%) 2835 (59.8%) 3045 (59.9%)
Diabetes mellitus 99 (28.6%) 1037 (21.9%) 1136 (22.3%)
Hyperlipidaemia 204 (59%) 2753 (58.1%) 2957 (58.2%)
Smoking
Current smoking 46 (13.3%) 797 (16.8%) 843 (16.6%)
Ex-smoker 118 (34.1%) 1615 (34.1%) 1733 (34.1%)
Never smoked 141 (41.6%) 1973 (41.7%) 2117 (41.6%)
Unknown 38 (11.0%) 352 (7.4%) 390 (7.7%)
Angina status
Atypical 175 (50.6%) 1727 (36.5%) 1902 (37.4%)
Typical 41 (11.8%) 1025 (21.6%) 1066 (21.0%)
Non-cardiac pain 8 (2.3%) 297 (6.3%) 305 (6.0%)
Dyspnoea 34 (9.8%) 472 (10.0%) 506 (10.0%)
None 73 (21.1%) 1164 (24.6%) 1237 (24.3%)
Unknown 15 (4.3%) 52 (1.1%) 67 (1.3%)
CCS angina class
Grade 1 18 (43.9%) 254 (24.8%) 272 (25.5%)
Grade II 16 (39.0%) 561 (54.7%) 577 (54.1%)
Grade III 5 (12.2%) 111 (10.8%) 116 (10.9%)
Grade IV 0 23 (2.2%) 23 (2.2%)
Unknown 2 (4.9%) 76 (7.4%) 78 (7.3%)
CCTA rejection rate 160 (3.1%)
Diamond–Forrester risk 46.8 (±19.9) 51.6 (±20.3) 51.3 (±20.3)
CTA, computed tomography angiography.
Advance FFRCT 3703
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Figure 1 Degree of coronary artery disease (% stenosis) and coronary computed tomography angiography-derived fractional flow reserve posi-
tive/negative ratio stratified by coronary artery territory: (A) left anterior descending; (B) left circumflex, and (C) right coronary artery.
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..was no significant difference between subject group demographics or
risk factors for those receiving CCTA alone vs. CCTA plus FFRCT.
Extent and severity of coronary artery
disease by coronary computed
tomography angiography and coronary
computed tomography angiography-
derived fractional flow reserve
Coronary atheroma >_50% DS was observed at CCTA in 72.1% of
subjects (n= 3398) and >70% DS in 32% (n= 1538). Two- or three-
vessel disease (>_50% DS) was present in 27.5% and 9.4%,
respectively. Ischaemia (FFRCT <_0.80) in at least one coronary
territory was present in 61.9% (n= 3145) of patients (Figure 1).
The LAD was more likely to have anatomically severe (>70% DS),
coronary disease (21.4%), and a positive FFRCT (n= 2760, 58.3%)
compared with other vessels: left circumflex (LCX) 23.8% (n= 1260),
right coronary artery (RCA) 22.1% (n= 1047) (P < 0.001). The
LAD exhibited significantly lower median FFRCT values (0.79: IQR
0.71–0.85) compared with the LCX (0.88: IQR 0.81–0.92) and
RCA (0.87: IQR 0.82–0.91), (P< 0.001). However, a positive
FFRCT in the mild-moderate (30–70%) stenosis range was more
likely in the LAD (55.3%) compared with LCX (31.7%) and RCA
(27.3%), (P< 0.001).
Figure 2 Clinical management strategies and reclassification of post-coronary computed tomography angiography, following coronary computed
tomography angiography-derived fractional flow reserve and actual management at 90 days (A Core and B Site).
..........................................................................................................................
....................................................................................................................................................................................................................
Table 2 FFRCT-determined treatment plan and actual clinical management at 90 days
Actual treatment Site-determined post-FFRCT treatment plan
Revascularization
(n51418)
Medications
(n5 2679)
Further diagnostics
(n5 121)
Total
(n5 4737)
MT 504 (35.5%) 2545 (95.0%) 92 (76.0%) 3573 (75.4%)
PCI 799 (56.3%) 115 (4.3%) 25 (20.7%) 1015 (21.4%)
CABG 115 (8.1%) 19 (0.7%) 4 (3.3%) 149 (3.1%)
.............................................................................................................................................................................
....................................................................................................................................................................................................................
Table 3 Actual treatment at 90 days (medical therapy vs. revascularization) stratified by coronary computed tomog-
raphy angiography-derived fractional flow reserve values (0.05 increments)
Actual treatment Site-determined post-FFRCT treatment plan
<0.71
(n5 1530)
0.71–0.75
(n5 615)
0.76–0.8
(n5 1000)
0.81–0.85
(n5867)
0.86–0.9
(n5 595)
>0.9
(n5 130)
Total
(n5 4737)
Medical treatment 709 (46.3%) 468 (76.1%) 874 (87.4%) 820 (94.6%) 578 (97.1%) 124 (95.4%) 3573 (75.4%)
Revascularization 821 (53.7%) 147 (23.9%) 126 (12.6%) 47 (5.4%) 17 (2.9%) 6 (4.6%) 1164 (24.6%)
Advance FFRCT 3705
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Recommended clinical management
strategies following coronary computed
tomography angiography-derived frac-
tional flow reserve
Coronary computed tomography angiography-derived fractional
flow reserve resulted in revision of the clinical management plan as
determined by the site investigators in 63.5% of patients (CI: 62.0–
65) when compared with initial CCTA-based treatment plan. Under
core laboratory analysis, FFRCT changed management plans in 66.9%
of patients (CI: 64.8–67.6). Reclassification patterns are shown in
Figure 2. Of 2386 (59.7%) patients in whom further information was
required after CCTA, FFRCT reclassified 70.0% (n= 1671) to medical
treatment (MT), 24.4% (n= 570) to PCI, 2.1% (n= 49) to CABG, and
only 2.6% (n= 121) were assigned to downstream testing. An initial
management decision for MT was assigned to 19.2% (n= 790), and
this assignment remained unchanged after FFRCT in 93% of cases,
with only 5.4% changing to revascularization (Table 2 and Figure 3).
However, among the 22.9% of subjects (n= 943) for whom the
CCTA-based management plan indicated revascularization, 22.3%
were reclassified to MT alone after FFRCT analysis (PCI to MT 20.9%,
n= 198; CABG to MT 1.4%, n= 12). A positive FFRCT (<_0.80)
Figure 3 Actual treatment at 90 days (medical therapy, percutaneous intervention, and coronary bypass grafting) by post-coronary computed
tomography angiography-derived fractional flow reserve treatment strategy.
Figure 4 Actual treatment at 90 days (medical therapy, percutaneous intervention, and coronary bypass grafting) stratified by coronary computed
tomography angiography-derived fractional flow reserve values (0.05 increments).
3706 T.A. Fairbairn et al.
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occurred in 61.9% of subjects, yet only 34.4% (site) and 46.8% (core)
of cases were recommended for revascularization despite the major-
ity of these patients, 69.5% (n= 984) having anatomically significant
disease (>50% DS) on CCTA. Over half of the deferrals from ICA,
53.9% (n= 762) had an FFRCT between 0.75 and 0.8, with patients
with lower FFRCT more likely to be recommended for ICA (Table 3).
Rate of non-obstructive angiography and
revascularization
The rate of anatomically defined ‘non-obstructive’ disease at ICA (no
stenosis >50% at ICA) was significantly lower in patients with FFRCT
<_0.80 (14.4%) vs. FFRCT >0.80 (43.8%), (OR 0.19, CI 0.15–0.25,
P< 0.001) (Figure 3).
When stratified by 0.05 categorical FFRCT increments, subjects
were significantly more likely to undergo ICA with decreasing FFRCT
(FFRCT <_0.70: 73.8% vs. FFRCT >0.80: 20.5%) and to be revascular-
ized at ICA (FFRCT <_0.70: 72.5% vs. FFRCT >0.80: 20.4% P< 0.001),
(Supplementary material online). In multivariable analysis, stenosis
>70%/occluded vessel (OR 5.85–6.36, P< 0.00105) and FFRCT <0.80
(OR 5.88, P< 0.001) were significant predictors of revascularization
(Table 4 and Figure 4), as were the presence of typical/atypical symp-
toms and male gender.
Major adverse cardiovascular events,
myocardial infarction, and death
No death or MI occurred within 90 days in any subject whose FFRCT
was >0.80 (n= 1592). Conversely, in patients with at least one FFRCT
value <_0.80 (n= 3145) there were 19 (0.6%, P< 0.01) MACE events;
4 MI, 5 urgent unplanned hospitalizations for ACS and urgent revas-
cularization and 10 deaths. These events predominantly occurred in
the lower FFRCT ranges below 0.76 (18 of 19), indicating that an
FFRCT <_0.80 increased the risk of an adverse event [MACE, hazard
ratio (HR) 19.75, CI 1.19–326], P = 0.0008 and 14 death/MI, HR
14.68, CI 0.88–246, P= 0.039], (Figure 5A and B).
Discussion
In this large prospective international multicentre registry, FFRCT
changed management recommendations from CCTA-based plans in
approximately two out of three subjects. A negative FFRCT was asso-
ciated with a low rate of invasive angiography or revascularization
within 90 days and with freedom from MI or death. In addition, there
was an inverse relationship between FFRCT and the likelihood of
downstream ICA, revascularization, and MACE.
Coronary computed tomography angiography is now considered
a reasonable or preferred first line investigation for patients with sus-
pected CAD,12–14 as studies have suggested improved clinical out-
comes for patients managed based on initial CCTA rather than
alternative non-invasive tests.4 While, CCTA has been proven to be
an effective diagnostic tool, there remain concerns regarding fairly
high rates of downstream ICA and resource utilization as well as the
lack of physiological information available to guide treatment deci-
sion-making.2,15,16 FFRCT has been proposed as a diagnostic tool to
help determine more appropriately who should proceed for ICA fol-
lowing CCTA.7,8,15,17 The PROMISE FFRCT retrospective sub-study
highlighted the potential of FFRCT to reduce ICA referral and enrich
the appropriateness of the population referred for ICA.17,18
Our findings based on prospective utilization of FFRCT after posi-
tive CCTA represent the first real-world multicentre evaluation of
the utility and safety of FFRCT. FFRCT led to a recommendation of
ICA in only 40% of subjects in a cohort with an anatomic obstructive
disease rate of 72%, and subjects referred for ICA downstream were
significantly more likely to have obstructive disease at ICA if they had
a positive FFRCT.
19–21
Management reclassification by FFRCT as expected occurred in all
directions. There was, however, a clear directed benefit in instances
of physician uncertainty expressed by the need for ‘further testing’, as
the majority of subjects (70%) were safely deferred to medical man-
agement alone. Importantly only in a very small minority of cases (0%
by core lab and 2.6% by site) was further testing deemed necessary
to determine CAD significance, thereby highlighting the improved
diagnostic certainty and the opportunity to reduce further down-
stream testing. Importantly, this approach of test layering not only
results in increased costs and at times additional radiation exposure,
it may not help discriminate those patients likely to benefit from
revascularization. In the recently published PACIFIC trial, hybrid test-
ing with a CTA/SPECT approach did not enhance on the accuracy
for the detection of lesions specific ischaemia beyond CCTA or
SPECT alone.22 In instances, when the physician recommendation
was for revascularization post-CCTA alone, FFRCT redirected man-
agement to medical therapy in close to 25% of cases, offering the po-
tential to avoid unnecessary ICA. This observation supports the
concept that CCTA alone could result in increased ICA without
revascularization.6 Interestingly a positive FFRCT (<_0.80) was not
.................................................................................................
Table 4 Multivariable logistic regression analysis of
univariate predictors of revascularization amongst sub-
jects with coronary computed tomography angiog-
raphy-derived fractional flow reserve performed as
compared to those subjects who did not undergo
revascularization
Covariates Estimates
of effect
Odds ratio P-value
Age (>_65) -0.0433 0.96 (0.81–1.14) 0.6189
Female gender -0.2953 0.74 (0.62–0.90) 0.0023
Hyperlipidaemia 0.3036 1.35 (1.14–1.61) 0.0005
Diabetes mellitus 0.0990 1.10 (0.91–1.33) 0.3066
Smoking 0.1150 1.12 (0.89–1.41) 0.3189
Symptom status
Typical angina 0.9898 2.69 (2.14–3.38) <0.0001
Atypical angina 0.2808 1.32 (1.06–1.61) 0.0129
Non-cardiac pain 0.1223 1.13 (0.76–1.89) 0.5400
Dyspnoea 0.3204 1.38 (1.00–1.89) 0.0472
Coronary stenosis >70% 1.7666 5.85 (4.95–6.91) <0.0001
FFRCT <_0.8 1.8959 5.88 (4.43–7.80) <0.0001
Intercept parameter estimate: -3.8806, P < 0.0001. Reference categories for cova-
riates: (i) age: ‘<_65 years’, (ii) ‘male sex’, (iii) ‘no hyperlipidaemia’, (iv) ‘no diabetes
mellitus’, (v) ‘no smoking’, (vi) no ‘typical angina’, ‘atypical angina’, ‘non-cardiac
pain’, or ‘dyspnoea’, (vii) coronary stenosis: ‘<_70%’, and (viii) FFRCT: ‘>0.8’.
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..followed by either ICA or revascularization in up to half of cases, des-
pite the majority having evidence of anatomical (>50% DS) significant
disease. This perhaps reflects nuanced management decisions
regarding factors such as diffuse atherosclerosis and the absence
of lesion specific ischaemia or other factors such as anatomical lo-
cation, comorbidities, and symptom severity. It is also important
to recognize that follow-up is limited to 90 days at present and
longer term follow-up will be valuable to assess whether these
medically managed FFRCT-positive patients will end up needing
revascularization over time is uncertain. These findings should
also be placed into the context of recent guidelines highlighting
the importance of guiding revascularization decision-making based
on anatomy and physiology emphasizing the value of FFRCT to
enable meaningful Heart Team discussions in a fashion that CTA
alone cannot.23,24
There is also growing awareness that while in a trial setting FFR
and FFRCT have been evaluated using a binary cut-off, in practice the
benefit from revascularization seems to increase with lower FFR val-
ues.21,25,26 Predictors of revascularization in this study were lesion
specific ischaemia by FFRCT, diameter stenosis >_70% and angina
Figure 5 Major adverse cardiac events (A) (all-cause mortality, myocardial infarction, unplanned hospitalization with urgent revascularization) and
(B) myocardial infarction/all-cause mortality alone at 90 days for coronary computed tomography angiography-derived fractional flow reserve posi-
tive (<_0.80) and negative values (>0.80).
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..symptoms. FFRCT, like all test results, needs to be integrated into the
overall clinical presentation including severity of symptoms. There
was a difference noted between site and core management plans in
the setting of positive FFRCT, with site management strategies being
more conservative in recommending ICA and revascularization
(34.4%), supporting the theory that there is a significant role in the in-
terpretation and clinical context of the FFRCT result, as sites were
privy to greater information of the clinical history and co-morbidities
whereas the core lab was not.
This international real-world registry has also highlighted patterns
of physician referral behaviour. The majority of lesions referred for
further investigation were in the LAD, which is greater than the
observed proportions of LAD disease burden in ICA studies,19 and
likely reflects heightened clinical concerns owing to the prognostic
importance of LAD disease. The varied correlation between degree
of stenosis and ischaemia is well known from studies such as FAME
and RIPCORD,27,28 which may result in a higher degree of uncer-
tainty and desire to know more information. The increased likelihood
of FFRCT-determined ischaemia in the mild-moderate (30–70%) de-
gree of anatomical stenosis in the LAD compared to other vessels is
of particular diagnostic use and given the high frequency in our pa-
tient population (55.3%), justifies clinicians’ vigilance in referring these
lesions to ICA.24,25
Beyond defining the clinical use and role of FFRCT, our data provide
meaningful insight into the potential prognostic value of FFRCT in clinic-
al practice. Importantly, a negative FFRCT was associated with an excel-
lent short-term prognosis, as none of the 1592 subjects with negative
FFRCT experienced death, MI, or unplanned hospitalization for ACS
and urgent revascularization. All MACE events occurred in subjects
with FFRCT <_0.80, with the majority of events in subjects with an
FFRCT <_0.75. This clustering of events in subjects with more significant
ischaemia is interesting, however, long-term clinical follow-up is
needed to determine if there is a relationship between the severity of
FFRCT reduction and adverse clinical outcomes. Our results mirror the
invasive physiology experience where lower FFR values have been
consistently shown to predict all-cause mortality and increased likeli-
hood of MI and urgent revascularization.29
Limitations
Our analysis is not without limitations. To start, while including a
broad sampling of patients undergoing FFRCT across many countries
and healthcare systems, ADVANCE is a registry, and therefore, we
cannot exclude some element of referral bias. As well, while sites
provided their treatment strategies on the basis of CCTA, virtually all
subjects had FFRCT available and therefore what their downstream
treatment would have been in absence of FFRCT cannot be deter-
mined with complete certainty. As such, while we report the change
in clinical recommendations following FFRCT as compared to CCTA
alone, through 90 days not all site recommendations were followed
clinically, highlighting the multifaceted nature of clinical decision-mak-
ing. In addition, while detailed case/incident reports were submitted
detailing all events, like many registries, a central event adjudication
committee was not used. Finally, the Follow-up reported represents
only the first 90 days, and although most adverse events and invasive
management strategies occur within this time, longer term follow-up
is essential particularly for MACE, and therefore is planned through 3
years in the ADVANCE registry.
Conclusions
In a large international multicentre population, FFRCT-modified treat-
ment recommendation in up to two-thirds of subjects as compared
to CCTA alone, was associated with fewer ICA without obstructive
disease, and predicted revascularization, while helping discriminate
subjects at lower risk of adverse events at 90 days.
Supplementary material
Supplementary material is available at European Heart Journal online.
Figure 6 Three-dimensional coronary computed tomography angiography-derived fractional flow reserve pressure model of (A) a 59-year-old
male with a 50–70% mid left anterior descending coronary artery stenosis yet severe ischaemia (coronary computed tomography angiography-
derived fractional flow reserve <_0.50) who experienced an NSTEMI in follow-up. (B) In comparison, a 71-year-old male with a more severe stenosis
(70–90%) in the mid-left anterior descending without lesion specific ischaemia (coronary computed tomography angiography-derived fractional flow
reserve 0.83) who was clinically well through 90 days follow-up.
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